Daily Stock Analysis, CTRV, ContraVir Pharmaceuticals Inc, priceseries

ContraVir Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.24
Close
0.23
High
0.24
Low
0.23
Previous Close
0.23
Daily Price Gain
0.00
YTD High
0.42
YTD High Date
Jan 11, 2019
YTD Low
0.22
YTD Low Date
Feb 19, 2019
YTD Price Change
-0.06
YTD Gain
-20.52%
52 Week High
2.60
52 Week High Date
May 29, 2018
52 Week Low
0.21
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-1.88
52 Week Gain
-89.06%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 7. 2017
11.44
Feb 21. 2017
12.34
9 Trading Days
7.84%
Link
LONG
Apr 19. 2017
12.88
Apr 20. 2017
13.84
1 Trading Days
7.45%
Link
LONG
Aug 17. 2017
4.72
Aug 21. 2017
4.96
2 Trading Days
5.08%
Link
LONG
Oct 2. 2017
4.24
Oct 6. 2017
4.68
4 Trading Days
10.38%
Link
LONG
Oct 12. 2017
5.65
Oct 13. 2017
5.94
1 Trading Days
5.15%
Link
Company Information
Stock Symbol
CTRV
Exchange
NasdaqCM
Company URL
http://www.contravir.com
Company Phone
732-902-4000
CEO
James E. Sapirstein
Headquarters
New Jersey
Business Address
399 THORNALL STREET, FIRST FLOOR, EDISON, NJ 08837
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001583771
About

ContraVir Pharmaceuticals, Inc. is a development stage biopharmaceutical company which is focused primarily on the development of drugs to treat herpes zoster or shingles. The company currently developing a compound called FV-100 for the treatment of shingles. It is also developing CMX157, a potent analog of the successful antiviral drug tenofovir DF. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.

Description

ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company is developing CMX157 and CRV431 to treat HBV infection; and FV-100, an orally available, small molecule compound for the prevention of post-herpetic neuralgia, and treatment of herpes zoster infection and acute zoster-associated pain. ContraVir Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Edison, New Jersey.